Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis
| Autor: | Mona Fouad, Omar Abdel-Rahman |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Risk
medicine.medical_specialty Mucocutaneous zone Antineoplastic Agents Subgroup analysis Lapatinib Neoplasms Internal medicine medicine Humans skin and connective tissue diseases Adverse effect Stomatitis Randomized Controlled Trials as Topic business.industry Pruritus Alopecia General Medicine medicine.disease Rash Surgery Clinical trial Meta-analysis Quinazolines Hand-Foot Syndrome medicine.symptom business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 31:975-986 |
| ISSN: | 1473-4877 0300-7995 |
| Popis: | We performed a systematic review and meta-analysis to determine the risk of mucocutaneous adverse events associated with lapatinib.Eligible studies included randomized phase II and III trials of patients with solid tumors on lapatinib; describing events of stomatitis, skin rash, hand foot syndrome, pruritus and alopecia.Our search strategy yielded 380 potentially relevant citations on lapatinib from PubMed/Medline, CENTRAL Cochrane Registry and ASCO Meeting Library. After exclusion of ineligible studies, a total of 19 clinical trials were considered eligible for the meta-analysis. The RRs of all-grade skin rash, stomatitis, hand foot syndrome and pruritus were 3.04 (95% CI 2.33-3.96; p 0.00001), 1.67 (95% CI 1.02-2.3; p 0.04), 4.45 (95% CI 1.15-17.19; p = 0.03), and 2.02 (95% CI 1.46-2.8; p 0.0001), respectively. Exploratory subgroup analysis showed no effect of treatment regimen on the RRs of the relevant adverse events.Our meta-analysis has demonstrated that lapatinib is associated with a significantly increased risk of all-grade skin rash, hand foot skin reaction and pruritus. Clinicians should be aware of these risks and perform regular clinical monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|